(Q36632760)

15 August 2017

1 reference

title

Modafinil reduces fatigue in Charcot-Marie-Tooth disease type 1A: a case series (English)

1 reference

Charcot-Marie-Tooth disease type 1A

15 August 2017

1 reference

1 reference

1

Gregory T Carter

1 reference

15 August 2017

Jay J Han

2

1 reference

15 August 2017

Angeli Mayadev

series ordinal

3

1 reference

15 August 2017

Michael D Weiss

series ordinal

4

1 reference

15 August 2017

publication date

1 October 2006

1 reference

American Journal of Hospice and Palliative Medicine

15 August 2017

published in

1 reference

15 August 2017

volume

23

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

412-416

1 reference

Population frequencies of inherited neuromuscular diseases—A world survey

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Electrodiagnostic evaluation of hereditary motor and sensory neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Neuropathic pain in Charcot-Marie-Tooth disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Evaluation of phrenic nerve and pulmonary function in hereditary motor and sensory neuropathy, type I

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

The reliability and validity of a self-report version of the FIM instrument in persons with neuromuscular disease and chronic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Fatigue and depression are associated with poor quality of life in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Exacerbated physical fatigue and mental fatigue in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Quality of life in multiple sclerosis: the impact of depression, fatigue and disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Quality of Life in Patients with Amyotrophic Lateral Sclerosis: Perceptions, Coping Resources, and Illness Characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Modafinil for excessive daytime sleepiness in myotonic dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Modafinil prevents glutamate cytotoxicity in cultured cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Modafinil increases histamine release in the anterior hypothalamus of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

Functional magnetic resonance imaging neuroactivation studies in normal subjects and subjects with the narcoleptic syndrome. Actions of modafinil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909106292169

21 January 2018

Identifiers

DOI

10.1177/1049909106292169

1 reference

15 August 2017

1 reference